2.1
Alirocumab (Praluent, Sanofi) is a monoclonal antibody that targets proprotein convertase subtilisin/kextin type 9 (PCSK9). It stops low‑density lipoprotein receptors in the liver from degrading, helping to lower levels of low‑density lipoprotein cholesterol (LDL‑C) in the blood. Alirocumab has a marketing authorisation in the UK for 'adults with primary hypercholesterolaemia (heterozygous‑familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet:
-
in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin or
-
alone or in combination with other lipid‑lowering therapies in patients who are statin‑intolerant, or for whom a statin is contraindicated.'
Alirocumab is given by subcutaneous injection. The recommended dose is either 75 mg or 150 mg every 2 weeks. In January 2021, the licensed dosage was updated to include another option of 300 mg every 4 weeks (monthly).